<SEC-DOCUMENT>0001193125-21-357380.txt : 20211215
<SEC-HEADER>0001193125-21-357380.hdr.sgml : 20211215
<ACCEPTANCE-DATETIME>20211215070557
ACCESSION NUMBER:		0001193125-21-357380
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211215
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211215
DATE AS OF CHANGE:		20211215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELI LILLY & Co
		CENTRAL INDEX KEY:			0000059478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				350470950
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06351
		FILM NUMBER:		211493080

	BUSINESS ADDRESS:	
		STREET 1:		LILLY CORPORATE CTR
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285
		BUSINESS PHONE:		3172762000

	MAIL ADDRESS:	
		STREET 1:		LILLY CORPORATE CENTER
		STREET 2:		DROP CODE 1094
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46285

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LILLY ELI & CO
		DATE OF NAME CHANGE:	19941024
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d212746d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lly="http://www.lilly.com/20211215" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2021-12-15_to_2021-12-15">ELI LILLY &amp; Co</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-12-15_to_2021-12-15">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-12-15_to_2021-12-15">0000059478</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="lly-20211215.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-12-15_to_2021-12-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> <xbrli:context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000059478</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-15</xbrli:startDate> <xbrli:endDate>2021-12-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-12-15_to_2021-12-15">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of Earliest Event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt:datemonthdayyearen">December 15, 2021</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">ELI LILLY AND COMPANY</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact Name of Registrant as Specified in its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt-sec:stateprovnameen">Indiana</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-12-15_to_2021-12-15">001-06351</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-12-15_to_2021-12-15">35-0470950</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br />of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification Number)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:49%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-12-15_to_2021-12-15">Lilly Corporate Center</ix:nonNumeric><br /><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-12-15_to_2021-12-15">Indianapolis</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt-sec:stateprovnameen">Indiana</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-12-15_to_2021-12-15">46285</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-12-15_to_2021-12-15">(317)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-12-15_to_2021-12-15">276-2000</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report.)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="text-decoration:underline">see</span> General Instruction A.2.):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:35%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br /></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br /></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember">Common Stock (no par value)</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember">LLY</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member">1.000% Notes due 2022</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member">LLY22</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member">7 1/8% Notes due 2025</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member">LLY25</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member">1.625% Notes due 2026</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member">LLY26</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member">2.125% Notes due 2030</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member">LLY30</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member">0.625% Notes due 2031</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member">LLY31</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member">0.500% Notes due 2033</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member">LLY33</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member">6.77% Notes due 2036</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member">LLY36</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member">1.625% Notes due 2043</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member">LLY43</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member">1.700% Notes due 2049</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member">LLY49A</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member">1.125% Notes due 2051</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member">LLY51</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member">1.375% Notes due 2061</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member">LLY61</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-12-15_to_2021-12-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;2.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&#160;15, 2021, Eli Lilly and Company (the &#8220;Company&#8221;) issued a press release updating its financial guidance for 2021 and announcing its financial guidance for 2022. In addition, on the same day, the Company held a teleconference for analysts and media to discuss this guidance. The teleconference was webcast on the Company&#8217;s website. The press release is attached to this Form <span style="white-space:nowrap">8-K</span> as Exhibit 99.1. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d212746dex991.htm">Press Release dated December&#160;15, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ELI LILLY AND COMPANY</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald A. Zakrowski</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Donald A. Zakrowski</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Vice President, Finance, and Chief Accounting Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">December&#160;15, 2021</td></tr>
</table></div>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d212746dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dec. 15, 2021 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">For&nbsp;Release:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Immediately</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Refer to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Molly McCully; <U>mccully_molly@lilly.com</U>; <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">317-478-5423</FONT></FONT> (Media)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kevin Hern; <U>hern_kevin_r@lilly.com</U>; 317-277-1838 (Investors)</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial
Guidance at Investment Community Meeting </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In today&#146;s presentations, Lilly will highlight newer medicines and upcoming launches expected to drive
growth through the decade &#150; showcasing how the company impacts millions of people and brings to life its purpose of creating medicines that make life better. </I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Lilly also will reinforce its commitment to innovation and investment in science to create the next wave of
new medicines for patients, share new information across its four therapeutic areas &#150; including pipeline and regulatory updates and new data readouts for early-phase molecules &#150; and provide visibility to future investments.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The company announces initiation of rolling submission to FDA for pirtobrutinib in mantle cell lymphoma,
reveals new phase 3 trials planned for tirzepatide in obesity outcomes, sleep apnea and kidney disease, and releases new biomarker data supporting donanemab efficacy.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Lilly expects 2022 revenue to be between $27.8</I><I></I><I>&nbsp;billion and
$28.3</I><I></I><I>&nbsp;billion, with key growth products driving <FONT STYLE="white-space:nowrap">two-thirds</FONT> of core business revenue, excluding <FONT STYLE="white-space:nowrap">COVID-19</FONT> therapies; expects operating margin to be
approximately 30</I><I></I><I>&nbsp;percent on a reported basis and approximately 32</I><I></I><I>&nbsp;percent on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis, and expects earnings per share (EPS) to be in the range of $8.00 to $8.15 on
a reported basis and $8.50 to $8.65 on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis.</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>The company now expects 2021 revenue to be between $28.0</I><I></I><I>&nbsp;billion and
$28.3</I><I></I><I>&nbsp;billion and EPS to be in the range of $6.18 to $6.23 on a reported basis and $8.15 to $8.20 on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INDIANAPOLIS, Dec. 15, 2021 &#150;&nbsp;Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&amp;D)
programs to highlight the company&#146;s strong pipeline and potential for future growth. At an investment community meeting today, the company is sharing key information across its four therapeutic areas &#150; including pipeline updates and future
R&amp;D investments &#150; along with 2022 financial guidance and updated 2021 guidance. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is on track to meet its goal of launching 20 new medicines over the <FONT
STYLE="white-space:nowrap">10-year</FONT> period from 2014 to 2023. Over the last eight years, Lilly has delivered 16 new medicines and plans to launch five more medicines over the next two years, if approved, including tirzepatide, donanemab,
pirtobrutinib, lebrikizumab and mirikizumab. These potential launches contribute to the company&#146;s expectations for <FONT STYLE="white-space:nowrap">top-tier,</FONT> volume-driven growth over the next decade, as the number of people that can
benefit from Lilly&#146;s innovative new medicines continues to increase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Lilly&#146;s accomplishments in recent years are impressive, but
it&#146;s where we are going that most excites us. We&#146;ve driven results over the last four years, successfully launched new medicines, and invested in high-impact R&amp;D that has set us up for a truly exciting new era,&#148; said David A.
Ricks, Lilly&#146;s chairman and CEO. &#147;Bringing new practice-changing medicines to patients is our top priority. We have a remarkable opportunity ahead of us to make life better for millions more people around the world.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is providing details on its diabetes and obesity, immunology, oncology and neuroscience R&amp;D programs, sharing a number of new pipeline updates
and previously undisclosed data. Lilly also will provide insight into its ongoing R&amp;D investments that reflect the company&#146;s conviction around key emerging trends in biopharma innovation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I&#146;m very optimistic about the future for Lilly and the patients we serve. In addition to our promising late-stage pipeline, our labs are making new
discoveries to bring life-changing medicines to patients who need them,&#148; said Daniel Skovronsky, M.D., Ph.D., Lilly&#146;s chief scientific and medical officer, and president of Lilly Research Laboratories. &#147;Lilly has significantly
improved our development speed and clinical success rates and will continue to apply this focus as we work to maximize the impact of our existing medicines and create new ones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Genetic medicines, including modalities such as RNA therapeutics and viral-delivered gene therapies, are poised to contribute to the next generation of
breakthrough treatments for a wide array of diseases,&#148; Skovronsky continued. &#147;Today, Lilly will share more about our new capabilities and increased investment in this space, along with new preclinical and clinical data for genetic
medicines in our neuroscience and cardiovascular disease research portfolios.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diabetes and Obesity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building on its historic foundation of helping people with diabetes, Lilly is expanding its strategic focus to breakthrough medications that disrupt the
disease cascade caused by obesity and type 2 diabetes progression, highlighted by tirzepatide and supported by several early-phase incretin assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted Lilly&#146;s
New Drug Application and Marketing Authorization Application, respectively, for tirzepatide for the treatment of adults with type 2 diabetes. Lilly also submitted tirzepatide to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan and in
six additional markets. Lilly plans to initiate additional tirzepatide studies that include phase 3 studies in obesity related outcomes and obstructive sleep apnea, as well as a phase 2 mechanism of action study in kidney disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lilly is disclosing new data from several assets in its robust early-phase incretin platform focused on obesity. The company&#146;s incretin platform is
focused on delivering therapeutics with bariatric surgery-like weight loss with related metabolic benefits and developing convenient, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">easy-to-use</FONT></FONT> oral incretins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As it has for nearly 100 years, Lilly continues to work to transform diabetes care through insulin innovation. Lilly&#146;s novel weekly insulin is on track
to progress to phase 3 studies in 2022, and the company is advancing a new generation of insulin medicines with its <FONT STYLE="white-space:nowrap">pre-clinical</FONT> efforts in glucose-sensing insulin. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immunology </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Over the last decade, Lilly has established a
presence in immunology, with Taltz<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Olumiant<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> addressing patient needs across dermatology and rheumatology. Positive late-stage
readouts in 2021 for mirikizumab in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severely</FONT></FONT> active ulcerative colitis and lebrikizumab in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> atopic dermatitis provide the potential to help even more patients suffering from disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Lilly has built a deep <FONT STYLE="white-space:nowrap">early-and</FONT> <FONT STYLE="white-space:nowrap">mid-stage</FONT> portfolio of novel
immunology opportunities that represent potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> assets
from both internal and external innovation. Lilly is sharing new data from several of these molecules, including proof of concept phase 1b atopic dermatitis data for its <FONT STYLE="white-space:nowrap">IL-2</FONT> conjugate, in collaboration with
Nektar Therapeutics, and is announcing plans to move into additional phase 2 studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Oncology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Propelled by the acquisition of Loxo Oncology, Lilly has established a renewed presence in oncology, with a portfolio focused on high-conviction assets. The
company&#146;s oncology portfolio, including Verzenio<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Retevmo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and pirtobrutinib, has the potential to deliver meaningful growth over
the course of the decade. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lilly initiated a rolling submission to the FDA for pirtobrutinib, seeking accelerated approval in mantle
cell lymphoma, with expectations to complete the submission in 2022 and regulatory action anticipated in early 2023. Lilly continues to invest to maximize the potential of Verzenio for patients, and intends to initiate a phase 3 study to evaluate
earlier treatment of prostate cancer in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company also is providing an overview of several promising
early-phase and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs that are expected to deliver new data and potential new trials starting in 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neuroscience </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lilly is an established leader in
neuroscience with a more than <FONT STYLE="white-space:nowrap">30-year</FONT> commitment to advancing Alzheimer&#146;s disease research. The company is focused on its work to slow, then halt and eventually prevent
<FONT STYLE="white-space:nowrap">age-related</FONT> neurodegeneration in the decades ahead. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lilly is providing new biomarker data from donanemab from the
phase 2 <FONT STYLE="white-space:nowrap">TRAILBLAZER-ALZ</FONT> study. Lilly initiated a rolling submission for donanemab to the FDA for accelerated approval in early Alzheimer&#146;s disease, which it expects to complete in the coming months,
likely by the end of the first quarter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is also sharing phase 1 data from its next-generation amyloid-lowering antibody, <FONT
STYLE="white-space:nowrap">N3PG-IV,</FONT> noting plans to move this antibody into pivotal trials in 2022. The company has a number of early phase and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> programs for Alzheimer&#146;s and other
neurodegenerative diseases with novel targets and new modalities and is highlighting the significant growth in its early pain pipeline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strong
Financial Outlook Fueled by New Innovative Medicines </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We believe the continued uptake of our key growth products &#150; which we expect will
account for more than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of core business revenue in 2022 &#150; coupled with our anticipated upcoming launches will allow Lilly to deliver <FONT STYLE="white-space:nowrap">top-tier,</FONT>
volume-driven revenue growth through at least 2030,&#148; said Anat Ashkenazi, Lilly senior vice president and chief financial officer. &#147;Lilly remains committed to prioritizing long-term growth, as we maintain significant investment in our
exciting pipeline, fund new launches to ensure we can reach more patients in the coming years and continue to expand operating margin.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Updated 2021 Financial Guidance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company has updated certain elements of its 2021 financial guidance on both a reported and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. Earnings
per share for 2021 are now expected to be in the range of $6.18 to $6.23 on a reported basis and $8.15 to $8.20 on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. The company&#146;s 2021 financial guidance reflects adjustments shown in the
reconciliation table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2021</B><br><B>Expectations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>% Change<BR>from 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Earnings per share (reported)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>6.18&nbsp;to&nbsp;$6.23</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>(9)%&nbsp;to&nbsp;(8)</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired IPR&amp;D<SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">.54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charge related to repurchase of higher-cost debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asset impairment, restructuring and other special charges<SUP
STYLE="font-size:85%; vertical-align:top">(b)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">COVID-19</FONT> antibodies inventory charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net gains on investments in equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Earnings per share <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8.15 to $8.20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>20%&nbsp;to&nbsp;21</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Numbers may not add due to rounding </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">includes costs related to business development transactions with Foghorn Therapeutics Inc., Rigel
Pharmaceuticals, Inc., Precision Biosciences, Inc., Protomer Technologies Inc., Kumquat Biosciences Inc., Merus N.V., Lycia Therapeutics Inc., Regor Therapeutics Group, ProQR Therapeutics N.V., MiNA Therapeutics Limited, and Asahi Kasei Pharma
Corporation. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">updated to include additional asset impairment primarily related to a contract-based intangible asset
recognized as a result of our acquisition of Loxo Oncology. This impairment is a result of a decision by Bayer to discontinue the development of a phase 1 molecule related to our contact-based intangible asset. &nbsp;&nbsp;&nbsp;&nbsp;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue for 2021 is now expected to be in the range of $28.0&nbsp;billion to $28.3&nbsp;billion, reflecting additional revenue from <FONT
STYLE="white-space:nowrap">COVID-19</FONT> antibodies associated with the recent purchase agreement with the U.S. Government and the channel impact of the updated 2022 NRDL formulary in China. Estimated revenue from
<FONT STYLE="white-space:nowrap">COVID-19</FONT> antibodies is now expected to be approximately $2.1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross margin as a percent of revenue
is still expected to be approximately 75&nbsp;percent on a reported basis and is now expected to be approximately 78&nbsp;percent on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing, selling and administrative expenses are still expected to be in the range of $6.2&nbsp;billion to $6.4&nbsp;billion. Research and development
expenses are still expected to be in the range of $6.9&nbsp;billion to $7.1&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating margin, defined as operating income as a percent of
revenue, is now expected to be approximately 23&nbsp;percent on a reported basis and still expected to be approximately 30&nbsp;percent on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (expense) is still expected to be expense in the range of $250&nbsp;million to
$150&nbsp;million on a reported basis and is still expected to be expense in the range of $100&nbsp;million to $0 on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. The estimate on a reported basis does not reflect fourth quarter <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> activity for equity investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 effective tax rate is
still expected to be approximately 11&nbsp;percent on a reported basis and approximately 13&nbsp;percent on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the company&#146;s updated 2021 financial guidance. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><B>2021 Guidance</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Prior</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Revised</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$27.2&nbsp;to&nbsp;$27.6&nbsp;billion</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$28.0&nbsp;to&nbsp;$28.3&nbsp;billion</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Margin % of Revenue (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 75%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Margin % of Revenue <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 79%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 78%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketing, Selling&nbsp;&amp; Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$6.2 to $6.4&nbsp;billion</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research&nbsp;&amp; Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$6.9 to $7.1&nbsp;billion</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Income/(Expense) (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$(250)&nbsp;to&nbsp;$(150)&nbsp;million</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Income/(Expense) <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$(100) million to $0</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Rate (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 11%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Rate <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 13%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$6.38 to $6.48</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$6.18 to $6.23</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$7.95 to $8.05</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$8.15 to $8.20</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Margin (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 24%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 23%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Margin <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Approx. 30%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Unchanged</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> guidance reflects adjustments presented in the earnings per share table
above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2022 Financial Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Earnings per share
for 2022 are expected to be in the range of&nbsp;$8.00&nbsp;to&nbsp;$8.15&nbsp;on a reported basis and&nbsp;$8.50&nbsp;to&nbsp;$8.65&nbsp;on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022<BR>Expectations</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Earnings per share (reported)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8.00&nbsp;to&nbsp;$8.15</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Earnings per share <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>8.50&nbsp;to&nbsp;$8.65</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company anticipates 2022 revenue between&nbsp;$27.8 billion&nbsp;and&nbsp;$28.3&nbsp;billion. Revenue growth is expected
to be driven by volume growth from key products including Trulicity<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Verzenio, Taltz, Jardiance<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Cyramza<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Emgality<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Tyvyt<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Retevmo and Olumiant. This growth is expected to be partially
offset by lower revenue for Alimta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> due to its loss of patent exclusivity, and significantly lower anticipated <FONT STYLE="white-space:nowrap">COVID-19</FONT> antibody revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gross margin as a percent of revenue is expected to be approximately 78&nbsp;percent on a reported basis and 80&nbsp;percent on a <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing, selling and administrative expenses are expected to be in the range of&nbsp;$6.4
billion&nbsp;to&nbsp;$6.6&nbsp;billion. Research and development expenses are expected to be in the range of&nbsp;$7.0 billion&nbsp;to&nbsp;$7.2&nbsp;billion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating margin for 2022 is expected to be approximately 30&nbsp;percent on a reported basis and approximately 32&nbsp;percent on a <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income (expense) is expected to be expense between&nbsp;$100&nbsp;million and $0&nbsp;on both a
reported basis and&nbsp;on a <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2022 effective tax rate is expected to be approximately 13 to
14&nbsp;percent on both a reported basis and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis, assuming no significant changes to U.S. tax policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the company&#146;s 2022 financial guidance. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022 Guidance</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$27.8&nbsp;to&nbsp;$28.3&nbsp;billion</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Margin % of Revenue (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Approx. 78%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross Margin % of Revenue <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Approx. 80%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketing, Selling&nbsp;&amp; Administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$6.4 to $6.6&nbsp;billion</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research&nbsp;&amp; Development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$7.0 to $7.2&nbsp;billion</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other Income/(Expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$(100) million to $0</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Approx. 13 to 14%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$8.00 to $8.15</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$8.50 to $8.65</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Margin (reported)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Approx. 30%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating Margin <FONT STYLE="white-space:nowrap">(non-GAAP)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Approx. 32%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> adjustments are consistent with the
earnings per share table above.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Webcast of Conference Call and Investor Materials </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously announced, investors and the general public can access a live webcast of the Investment Community Meeting, including a presentation of the
company&#146;s 2022 and updated 2021 guidance, through a link on Lilly&#146;s website at <U>www.lilly.com</U>. The conference call will begin at 9 a.m. Eastern time today and will be available for replay via the website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eli Lilly and Company</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lilly is a global healthcare
leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain
true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy
and volunteerism. To learn more about Lilly, please visit us at <U>www.lilly.com</U> and <U>www.lilly.com/news</U>. <FONT STYLE="white-space:nowrap">F-LLY</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains management&#146;s current intentions and expectations for the future, all of which are forward-looking statements within the
meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934. The words &#147;estimate&#148;, &#147;project&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;believe&#148;,
&#147;target&#148;, &#147;anticipate&#148; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. The following include some but not all of the factors that could
cause actual results or events to differ materially from those anticipated, including the impact of the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the global response thereto; uncertainties related to the company&#146;s
efforts to develop potential treatments for <FONT STYLE="white-space:nowrap">COVID-19;</FONT> the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of
obtaining regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approvals; the impact of acquisitions and business development transactions and related integration costs; the expiration of intellectual property protection for certain of the company&#146;s
products and competition from generic and/or biosimilar products; the company&#146;s ability to protect and enforce patents and other intellectual property; changes in patent law or regulations related to data package exclusivity; competitive
developments affecting current products and the company&#146;s pipeline; market uptake of recently launched products; information technology system inadequacies, breaches, or operating failures; unauthorized access, disclosure, misappropriation, or
compromise of confidential information or other data stored in the company&#146;s IT systems, networks, and facilities, or those of third parties with whom the company shares its data; unexpected safety or efficacy concerns associated with the
company&#146;s products; litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as the company is largely self-insured; issues with product supply and regulatory approvals
stemming from manufacturing difficulties or disruptions, including as a result of regulatory actions related to our facilities; reliance on third-party relationships and outsourcing arrangements; regulatory changes or other developments; regulatory
actions regarding currently marketed products; continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; devaluations in foreign currency exchange
rates or changes in interest rates, and inflation; changes in tax law, tax rates, or events that differ from the company&#146;s assumptions related to tax positions; asset impairments and restructuring charges; the impact of global macroeconomic
conditions and trade disruptions or disputes; changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); and regulatory compliance problems or government
investigations. In addition, the company may not be able to reliably predict the impact of specified items in its 2022 guidance beyond the next 12 months, and the variability of factors discussed in these forward-looking statements could have a
significant and unpredictable impact on the company&#146;s future GAAP results. For additional information about the factors that could cause actual results to differ materially from forward-looking statements, please see the company&#146;s latest
Form <FONT STYLE="white-space:nowrap">10-K</FONT> and subsequent Forms <FONT STYLE="white-space:nowrap">8-K</FONT> and <FONT STYLE="white-space:nowrap">10-Q</FONT> filed with the SEC. You should not place undue reliance on forward-looking
statements, which speak only as of the date of this release. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this
release. The company uses <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures that differ from financial statements reported in conformity with U.S. generally accepted accounting principles (&#147;GAAP&#148;), and this press release
includes a description of certain <FONT STYLE="white-space:nowrap">non-GAAP</FONT> items that may affect the company&#146;s financial expectations for 2021 and 2022. The company&#146;s <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial
measures adjust reported results to exclude amortization of intangibles and items that are typically highly variable, difficult to predict, and/or of a size that could have a substantial impact on the company&#146;s reported operations for a period.
The company believes that these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures provide useful information to investors in evaluating the company&#146;s performance. They can assist in making meaningful period-over-period
comparisons and in identifying operating trends that would otherwise be masked or distorted by the items subject to the adjustments. Management uses these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures internally to evaluate the
performance of the company&#146;s business, including to allocate resources and to evaluate results relative to incentive compensation targets. Investors should consider these <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial measures in
addition to, not as a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;#&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;# </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U></U>Alimta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (pemetrexed disodium, Lilly)<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cyramza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(ramucirumab, Lilly) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emgality<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(galcanezumab-gnlm, Lilly) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jardiance<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(empagliflozin, Boehringer Ingelheim) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Olumiant<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(baricitinib, Lilly) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Retevmo<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (selpercatinib, Lilly) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taltz<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(ixekizumab, Lilly)
Trulicity<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(dulaglutide, Lilly) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tyvyt<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>(sintilimab injection, Lilly) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Verzenio<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;(abemaciclib, Lilly) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lly-20211215.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/15/2021 12:58:03 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:lly="http://www.lilly.com/20211215"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.lilly.com/20211215"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
    <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211215_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211215_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lly-20211215_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="lly_DocumentAndEntityInformationTable" name="DocumentAndEntityInformationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_DocumentAndEntityInformationLineItems" name="DocumentAndEntityInformationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A1.000NotesDueJune22022Member" name="A1.000NotesDueJune22022Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A718NotesDueJune12025Member" name="A718NotesDueJune12025Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A1.625NotesDueJune22026Member" name="A1.625NotesDueJune22026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A2.125NotesDueJune32030Member" name="A2.125NotesDueJune32030Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A625Notesdue2031Member" name="A625Notesdue2031Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A5000NotesDue2033Member" name="A5000NotesDue2033Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A6.77NotesDueJanuary12036Member" name="A6.77NotesDueJanuary12036Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A1625NotesDue2043Member" name="A1625NotesDue2043Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A1.700Notesdue2049Member" name="A1.700Notesdue2049Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A1125NotesDue2051Member" name="A1125NotesDue2051Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="lly_A1375NotesDue2061Member" name="A1375NotesDue2061Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>lly-20211215_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/15/2021 12:58:05 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef roleURI="http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lly-20211215.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="lly-20211215.xsd#lly_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="lly_DocumentAndEntityInformationTable" />
    <link:loc xlink:href="lly-20211215.xsd#lly_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="lly_DocumentAndEntityInformationLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.000NotesDueJune22022Member" xlink:type="locator" xlink:label="lly_A1.000NotesDueJune22022Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A718NotesDueJune12025Member" xlink:type="locator" xlink:label="lly_A718NotesDueJune12025Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.625NotesDueJune22026Member" xlink:type="locator" xlink:label="lly_A1.625NotesDueJune22026Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A2.125NotesDueJune32030Member" xlink:type="locator" xlink:label="lly_A2.125NotesDueJune32030Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A625Notesdue2031Member" xlink:type="locator" xlink:label="lly_A625Notesdue2031Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A5000NotesDue2033Member" xlink:type="locator" xlink:label="lly_A5000NotesDue2033Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A6.77NotesDueJanuary12036Member" xlink:type="locator" xlink:label="lly_A6.77NotesDueJanuary12036Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1625NotesDue2043Member" xlink:type="locator" xlink:label="lly_A1625NotesDue2043Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.700Notesdue2049Member" xlink:type="locator" xlink:label="lly_A1.700Notesdue2049Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1125NotesDue2051Member" xlink:type="locator" xlink:label="lly_A1125NotesDue2051Member" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1375NotesDue2061Member" xlink:type="locator" xlink:label="lly_A1375NotesDue2061Member" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="lly_DocumentAndEntityInformationTable" order="1" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="lly_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="23.0001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="24" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1.000NotesDueJune22022Member" order="25" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A718NotesDueJune12025Member" order="26" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1.625NotesDueJune22026Member" order="27" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A2.125NotesDueJune32030Member" order="28" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A625Notesdue2031Member" order="29" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A5000NotesDue2033Member" order="30" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A6.77NotesDueJanuary12036Member" order="31" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1625NotesDue2043Member" order="32" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1.700Notesdue2049Member" order="33" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1125NotesDue2051Member" order="34" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1375NotesDue2061Member" order="35" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="37.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="38.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="39.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="43.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="44.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="45.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="46.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="47.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="48.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="49.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="50.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="51.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="52.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="53.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="54.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="55.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="56.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="57.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="58.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="59.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="60.001" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="61.001" priority="2" use="optional" />
  </link:definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>lly-20211215_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/15/2021 12:58:03 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="lly_DocumentAndEntityInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_DocumentAndEntityInformationTable" xlink:to="lly_DocumentAndEntityInformationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_DocumentAndEntityInformationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Table]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="lly_DocumentAndEntityInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="lly_DocumentAndEntityInformationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_DocumentAndEntityInformationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document And Entity Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Class A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonClassAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Class A [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.000NotesDueJune22022Member" xlink:type="locator" xlink:label="lly_A1.000NotesDueJune22022Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A1.000NotesDueJune22022Member" xlink:to="lly_A1.000NotesDueJune22022Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A1.000NotesDueJune22022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1.000 Notes Due June 22022 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A1.000NotesDueJune22022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1.000 Notes Due June 22022 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A718NotesDueJune12025Member" xlink:type="locator" xlink:label="lly_A718NotesDueJune12025Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A718NotesDueJune12025Member" xlink:to="lly_A718NotesDueJune12025Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A718NotesDueJune12025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 718 Notes Due June 12025 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A718NotesDueJune12025Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 718 Notes Due June 12025 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.625NotesDueJune22026Member" xlink:type="locator" xlink:label="lly_A1.625NotesDueJune22026Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A1.625NotesDueJune22026Member" xlink:to="lly_A1.625NotesDueJune22026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A1.625NotesDueJune22026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1.625 Notes Due June 22026 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A1.625NotesDueJune22026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1.625 Notes Due June 22026 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A2.125NotesDueJune32030Member" xlink:type="locator" xlink:label="lly_A2.125NotesDueJune32030Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A2.125NotesDueJune32030Member" xlink:to="lly_A2.125NotesDueJune32030Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A2.125NotesDueJune32030Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 2.125 Notes Due June 32030 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A2.125NotesDueJune32030Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 2.125 Notes Due June 32030 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A625Notesdue2031Member" xlink:type="locator" xlink:label="lly_A625Notesdue2031Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A625Notesdue2031Member" xlink:to="lly_A625Notesdue2031Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A625Notesdue2031Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 625 Notesdue 2031 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A625Notesdue2031Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 625 Notesdue 2031 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A5000NotesDue2033Member" xlink:type="locator" xlink:label="lly_A5000NotesDue2033Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A5000NotesDue2033Member" xlink:to="lly_A5000NotesDue2033Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A5000NotesDue2033Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 5000 Notes Due 2033 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A5000NotesDue2033Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 5000 Notes Due 2033 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A6.77NotesDueJanuary12036Member" xlink:type="locator" xlink:label="lly_A6.77NotesDueJanuary12036Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A6.77NotesDueJanuary12036Member" xlink:to="lly_A6.77NotesDueJanuary12036Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A6.77NotesDueJanuary12036Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 6.77 Notes Due January 12036 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A6.77NotesDueJanuary12036Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 6.77 Notes Due January 12036 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A1625NotesDue2043Member" xlink:type="locator" xlink:label="lly_A1625NotesDue2043Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A1625NotesDue2043Member" xlink:to="lly_A1625NotesDue2043Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A1625NotesDue2043Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1625 Notes Due 2043 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A1625NotesDue2043Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1625 Notes Due 2043 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.700Notesdue2049Member" xlink:type="locator" xlink:label="lly_A1.700Notesdue2049Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A1.700Notesdue2049Member" xlink:to="lly_A1.700Notesdue2049Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A1.700Notesdue2049Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1.700 Notesdue 2049 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A1.700Notesdue2049Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1.700 Notesdue 2049 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A1125NotesDue2051Member" xlink:type="locator" xlink:label="lly_A1125NotesDue2051Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A1125NotesDue2051Member" xlink:to="lly_A1125NotesDue2051Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A1125NotesDue2051Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1125 Notes Due 2051 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A1125NotesDue2051Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1125 Notes Due 2051 [Member]</link:label>
    <link:loc xlink:href="lly-20211215.xsd#lly_A1375NotesDue2061Member" xlink:type="locator" xlink:label="lly_A1375NotesDue2061Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lly_A1375NotesDue2061Member" xlink:to="lly_A1375NotesDue2061Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="lly_A1375NotesDue2061Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A 1375 Notes Due 2061 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="lly_A1375NotesDue2061Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">A 1375 Notes Due 2061 [Member]</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>lly-20211215_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 12/15/2021 12:58:03 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lly-20211215.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="lly-20211215.xsd#lly_DocumentAndEntityInformationTable" xlink:type="locator" xlink:label="lly_DocumentAndEntityInformationTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="lly_DocumentAndEntityInformationTable" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_DocumentAndEntityInformationLineItems" xlink:type="locator" xlink:label="lly_DocumentAndEntityInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationTable" xlink:to="lly_DocumentAndEntityInformationLineItems" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:type="locator" xlink:label="us-gaap_CommonClassAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.000NotesDueJune22022Member" xlink:type="locator" xlink:label="lly_A1.000NotesDueJune22022Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1.000NotesDueJune22022Member" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A718NotesDueJune12025Member" xlink:type="locator" xlink:label="lly_A718NotesDueJune12025Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A718NotesDueJune12025Member" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.625NotesDueJune22026Member" xlink:type="locator" xlink:label="lly_A1.625NotesDueJune22026Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1.625NotesDueJune22026Member" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A2.125NotesDueJune32030Member" xlink:type="locator" xlink:label="lly_A2.125NotesDueJune32030Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A2.125NotesDueJune32030Member" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A625Notesdue2031Member" xlink:type="locator" xlink:label="lly_A625Notesdue2031Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A625Notesdue2031Member" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A5000NotesDue2033Member" xlink:type="locator" xlink:label="lly_A5000NotesDue2033Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A5000NotesDue2033Member" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A6.77NotesDueJanuary12036Member" xlink:type="locator" xlink:label="lly_A6.77NotesDueJanuary12036Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A6.77NotesDueJanuary12036Member" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1625NotesDue2043Member" xlink:type="locator" xlink:label="lly_A1625NotesDue2043Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1625NotesDue2043Member" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1.700Notesdue2049Member" xlink:type="locator" xlink:label="lly_A1.700Notesdue2049Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1.700Notesdue2049Member" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1125NotesDue2051Member" xlink:type="locator" xlink:label="lly_A1125NotesDue2051Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1125NotesDue2051Member" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="lly-20211215.xsd#lly_A1375NotesDue2061Member" xlink:type="locator" xlink:label="lly_A1375NotesDue2061Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="lly_A1375NotesDue2061Member" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityRegistrantName" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_AmendmentFlag" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentType" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityFileNumber" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="47.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="48.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="49.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="50.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="51.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_CityAreaCode" order="52.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="53.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_WrittenCommunications" order="54.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_SolicitingMaterial" order="55.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementTenderOffer" order="56.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_PreCommencementIssuerTenderOffer" order="57.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_Security12bTitle" order="58.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_TradingSymbol" order="59.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_SecurityExchangeName" order="60.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lly_DocumentAndEntityInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="61.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d212746d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lly="http://www.lilly.com/20211215"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lly-20211215.xsd" xlink:type="simple"/>
    <context id="duration_2021-12-15_to_2021-12-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.000NotesDueJune22022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A718NotesDueJune12025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.625NotesDueJune22026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A2.125NotesDueJune32030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A625Notesdue2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A5000NotesDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A6.77NotesDueJanuary12036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1625NotesDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1.700Notesdue2049Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1125NotesDue2051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <context id="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000059478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">lly:A1375NotesDue2061Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-15</startDate>
            <endDate>2021-12-15</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2021-12-15_to_2021-12-15"
      id="Hidden_dei_EntityRegistrantName">ELI LILLY &amp; Co</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2021-12-15_to_2021-12-15">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-12-15_to_2021-12-15"
      id="Hidden_dei_EntityCentralIndexKey">0000059478</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-12-15_to_2021-12-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-12-15_to_2021-12-15">2021-12-15</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-12-15_to_2021-12-15">IN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-12-15_to_2021-12-15">001-06351</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-12-15_to_2021-12-15">35-0470950</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-12-15_to_2021-12-15">Lilly Corporate Center</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-12-15_to_2021-12-15">Indianapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-12-15_to_2021-12-15">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-12-15_to_2021-12-15">46285</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-12-15_to_2021-12-15">(317)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-12-15_to_2021-12-15">276-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-12-15_to_2021-12-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-12-15_to_2021-12-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-12-15_to_2021-12-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-12-15_to_2021-12-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember">Common Stock (no par value)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember">LLY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_us-gaap-CommonClassAMember">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member">1.000% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member">LLY22</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.000NotesDueJune22022Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member">7 1/8% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member">LLY25</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A718NotesDueJune12025Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member">LLY26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.625NotesDueJune22026Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member">2.125% Notes due 2030</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member">LLY30</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A2.125NotesDueJune32030Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member">0.625% Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member">LLY31</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A625Notesdue2031Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member">0.500% Notes due 2033</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member">LLY33</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A5000NotesDue2033Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member">6.77% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member">LLY36</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A6.77NotesDueJanuary12036Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member">1.625% Notes due 2043</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member">LLY43</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1625NotesDue2043Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member">1.700% Notes due 2049</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member">LLY49A</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1.700Notesdue2049Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member">1.125% Notes due 2051</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member">LLY51</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1125NotesDue2051Member">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member">1.375% Notes due 2061</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member">LLY61</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-12-15_to_2021-12-15_us-gaap-StatementClassOfStockAxis_lly-A1375NotesDue2061Member">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-12-15_to_2021-12-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140048484786808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELI LILLY & Co<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000059478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 15,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-06351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">35-0470950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Lilly Corporate Center<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Indianapolis<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">276-2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock (no par value)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member', window );">A 1.000 Notes Due June 22022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.000% Notes due 2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member', window );">A 718 Notes Due June 12025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">7 1/8% Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member', window );">A 1.625 Notes Due June 22026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member', window );">A 2.125 Notes Due June 32030 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">2.125% Notes due 2030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member', window );">A 625 Notesdue 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.625% Notes due 2031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member', window );">A 5000 Notes Due 2033 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">0.500% Notes due 2033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member', window );">A 6.77 Notes Due January 12036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">6.77% Notes due 2036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member', window );">A 1625 Notes Due 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.625% Notes due 2043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member', window );">A 1.700 Notesdue 2049 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.700% Notes due 2049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY49A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member', window );">A 1125 Notes Due 2051 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.125% Notes due 2051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member', window );">A 1375 Notes Due 2061 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lly_DocumentAndEntityInformationLineItems', window );"><strong>Document And Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">1.375% Notes due 2061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LLY61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lly_DocumentAndEntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lly_DocumentAndEntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lly_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.000NotesDueJune22022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A718NotesDueJune12025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.625NotesDueJune22026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A2.125NotesDueJune32030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A625Notesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A5000NotesDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A6.77NotesDueJanuary12036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1625NotesDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1.700Notesdue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1125NotesDue2051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=lly_A1375NotesDue2061Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MJ#QN[:HB >G'S_,8-<LC #(^"B!C &3<!B )$;=KZO(\CQ&Z5PP V3\4D(2
MR2-N!?C8;XN/A-"^//:V=M#:W<CON?U_>LDR,34Z3M>./+7:X+LZT')1;:J]
MDUK+O'HY%SP1RIY@/I]*TR'K [M/=[/-^N(_4$L#!!0    ( +PXCU.?H!OP
ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ O#B/4YE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" "\.(]3JAU2O/8&  !R+0  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ O#B/4Y^@&_"Q @  X@P   T
M             ( !.0\  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "\.(]3
MEXJ[',     3 @  "P              @ $5$@  7W)E;',O+G)E;'-02P$"
M% ,4    " "\.(]3'#AEZC\!   \ @  #P              @ '^$@  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ O#B/4R0>FZ*M    ^ $  !H
M         ( !:A0  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ O#B/4V60>9(9 0  SP,  !,              ( !3Q4  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  F18

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>13</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>12</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d212746d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d212746d8k.htm">d212746d8k.htm</File>
    <File>d212746dex991.htm</File>
    <File>lly-20211215.xsd</File>
    <File>lly-20211215_def.xml</File>
    <File>lly-20211215_lab.xml</File>
    <File>lly-20211215_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d212746d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 1,
   "contextCount": 13,
   "dts": {
    "definitionLink": {
     "local": [
      "lly-20211215_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "d212746d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lly-20211215_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lly-20211215_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lly-20211215.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 39,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 11,
   "memberStandard": 1,
   "nsprefix": "lly",
   "nsuri": "http://www.lilly.com/20211215",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d212746d8k.htm",
      "contextRef": "duration_2021-12-15_to_2021-12-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d212746d8k.htm",
      "contextRef": "duration_2021-12-15_to_2021-12-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 12,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "lly_A1.000NotesDueJune22022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1.000 Notes Due June 22022 [Member]",
        "terseLabel": "A 1.000 Notes Due June 22022 [Member]"
       }
      }
     },
     "localname": "A1.000NotesDueJune22022Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.625NotesDueJune22026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1.625 Notes Due June 22026 [Member]",
        "terseLabel": "A 1.625 Notes Due June 22026 [Member]"
       }
      }
     },
     "localname": "A1.625NotesDueJune22026Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1.700Notesdue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1.700 Notesdue 2049 [Member]",
        "terseLabel": "A 1.700 Notesdue 2049 [Member]"
       }
      }
     },
     "localname": "A1.700Notesdue2049Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1125NotesDue2051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1125 Notes Due 2051 [Member]",
        "terseLabel": "A 1125 Notes Due 2051 [Member]"
       }
      }
     },
     "localname": "A1125NotesDue2051Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1375NotesDue2061Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1375 Notes Due 2061 [Member]",
        "terseLabel": "A 1375 Notes Due 2061 [Member]"
       }
      }
     },
     "localname": "A1375NotesDue2061Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A1625NotesDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 1625 Notes Due 2043 [Member]",
        "terseLabel": "A 1625 Notes Due 2043 [Member]"
       }
      }
     },
     "localname": "A1625NotesDue2043Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A2.125NotesDueJune32030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 2.125 Notes Due June 32030 [Member]",
        "terseLabel": "A 2.125 Notes Due June 32030 [Member]"
       }
      }
     },
     "localname": "A2.125NotesDueJune32030Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A5000NotesDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 5000 Notes Due 2033 [Member]",
        "terseLabel": "A 5000 Notes Due 2033 [Member]"
       }
      }
     },
     "localname": "A5000NotesDue2033Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A6.77NotesDueJanuary12036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 6.77 Notes Due January 12036 [Member]",
        "terseLabel": "A 6.77 Notes Due January 12036 [Member]"
       }
      }
     },
     "localname": "A6.77NotesDueJanuary12036Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A625Notesdue2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 625 Notesdue 2031 [Member]",
        "terseLabel": "A 625 Notesdue 2031 [Member]"
       }
      }
     },
     "localname": "A625Notesdue2031Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_A718NotesDueJune12025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "A 718 Notes Due June 12025 [Member]",
        "terseLabel": "A 718 Notes Due June 12025 [Member]"
       }
      }
     },
     "localname": "A718NotesDueJune12025Member",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "lly_DocumentAndEntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Line Items]",
        "terseLabel": "Document And Entity Information [Line Items]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationLineItems",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "lly_DocumentAndEntityInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information [Table]",
        "terseLabel": "Document And Entity Information [Table]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationTable",
     "nsuri": "http://www.lilly.com/20211215",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.lilly.com//20211215/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-357380-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-357380-xbrl.zip
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M&5P^4>HFPA(3EE&9CBL<'04Y3!@U\:_/?8M=G17_N"B%/^'>@/F48 E%]M^
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MSO<!@JCE>JU2.5]FWU7F7,H^T[UDOD?)FQEZX:66PE6D#U# K$*(.[/OUPD
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M/-XZ4'Y!1^1?%_^^J:O\*#KQZJ4OZ/X^K$ZXAP7^93;#7:,3Z4FSQ$/L5;L
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M7FX:[;Q^_V7_#_CPU]-/1[O_#U!+ P04    " "\.(]3Q*&'W*@$  "'&
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M1M&P78311J7Z0(<H*_+"=<:#*!@$+5G]H$.459<A+0A0#5MZ.JR'*&38./K
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M W5F^M=:=+.FGAP'7 MNXC24XJ)KN<V:B/)-^%ASUVZNYCT77RMV&J5X=U.
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MP&Y@M!805$VW"#K$%G"OI]X"5J*T6J!LZ=F2,%C/T/LMV5V97BV&JJ*L;*Y
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M5D#B&9J1U(QPA&IHAQ(:AC;143UQS8[8R?)4F/_CB>S,_P%02P,$%     @
MO#B/4PY'?DAO!@  V4@  !0   !L;'DM,C R,3$R,35?<')E+GAM;-6<77/B
M-A2&[W=F_X/JO6EG:OQ!@(19=H>2I$.;KPELV^E-1M@"-"M+C&02^/>5C+5C
M@^W8Z;:@7 00.D?G/8\DR[+-Q\^;B(!GQ 5F=&!Y+=<"B 8LQ'0QL-;"AB+
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MC3XZ!RF3,7]5/\BS^T;]4S\O(TO^ 5!+ 0(4 Q0    ( +PXCU-AK:9H/A(
M !.L   .              "  0    !D,C$R-S0V9#AK+FAT;5!+ 0(4 Q0
M   ( +PXCU,R>]*0F"D  &_U   1              "  6H2  !D,C$R-S0V
M9&5X.3DQ+FAT;5!+ 0(4 Q0    ( +PXCU/$H8?<J 0  (<8   0
M      "  3$\  !L;'DM,C R,3$R,34N>'-D4$L! A0#%     @ O#B/4\P7
M>[>Q!@  QD(  !0              ( !!T$  &QL>2TR,#(Q,3(Q-5]D968N
M>&UL4$L! A0#%     @ O#B/4V;C2GV7"0  ?W,  !0              ( !
MZD<  &QL>2TR,#(Q,3(Q-5]L86(N>&UL4$L! A0#%     @ O#B/4PY'?DAO
M!@  V4@  !0              ( !LU$  &QL>2TR,#(Q,3(Q-5]P<F4N>&UL
64$L%!@     &  8 ?P$  %18      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
